NewAmsterdam Pharma Company N.V. (NAMS) stock analysis

NAMS · NewAmsterdam Pharma Company N.V.

Latest recorded price: USD 19.46

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: free cash flow margin -657.8%, ROIC -323.1%. The model flags 3 risk signals for this company (2 high severity).

Similar companies in Healthcare